ARCHIVES

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

This article is from The Cancer Letter archive.

Vol. 07 No. 15 | April 10, 1981

Download PDF Visit The Full Archive

Related Articles

Flavopiridol Plus Cisplatin Tested In Phase II Trial

October 26, 2007

Researchers Find Two Types Of MCL Drug Resistance

August 29, 2014

Pretreatment with Azacitidine Achieves 28-Month Remission

August 30, 2013

NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.

March 19, 2004

ACCC Members To Lobby, Hear Discussion on Oncology Unit

January 6, 1978

House Passes Cancer Bill With Mandates for NCI

September 28, 2012